Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Clinical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters Following Neoadjuvant Anti-PD-1 (Nivolumab), or the Combination of Anti-PD-1 Plus Anti-CTLA-4 (Nivolumab Plus Ipilimumab) in Patients With Surgically Accessible Glioblastoma

NCT04606316 is registered in ClinicalTrials.gov with Patrick Wen, MD as lead sponsor.

NCT NCT04606316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04606316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Clinical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters Following Neoadjuvant Anti-PD-1 (Nivolumab), or the Combination of Anti-PD-1 Plus Anti-CTLA-4 (Nivolumab Plus Ipilimumab) in Patients With Surgically Accessible Glioblastoma
Lead sponsor
Patrick Wen, MD
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 1, 2021
Completion date
December 31, 2026
Enrollment
63 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

gbm, glioblastoma, glioblastoma multiforme, grade iv astrocytoma